Proteome in Tandem with mystery partner
Published: 11:21 Friday 01 April 2005
By: Douglas Bence, Companies Correspondent
Shares in AIM-listed Proteome Sciences raced ahead on news that the Surrey-based company is about to sign an exclusive licensing deal with a 'major global healthcare player' for its Tandem Mass Tags, reagents used in protein research.
When the deal is signed Proteome (PRM) will receive $2.3 million (1.2 million) in milestone payments and a signing on fee.
Royalty payments will be in double digits, the company said in a trading statement, unusually high for the healthcare market.
The shares added 12p to 71.5p, a rise of 20.17% with four times the usual daily number changing hands in the first two hours trading.
Although Heads of Agreement have been signed and negotiations are advanced, no further details are being released and the partner remains unidentified.
The company has also completed its first deal with Regen Therapeutics involving Colostrinin, a proline-rich polypeptide complex derived from bovine colostrums, which is being developed for veterinary use.
Colostrinin, or small molecular weight compounds based on them, may have potential as pharmaceutical agents for the treatment of Alzheimer's and other
neurodegenerative diseases.
Proteome Sciences has recently raised 4.7 million with a share placing of 8 million new shares at 59.5p with an institution, 6.6% of the equity.
Chief executive Christopher Pearce is also putting an additional 255,000 into the company by exercising warrants.
Proteomics is the study of proteins and may eventually help the big pharmaceutical groups overcome the major clinical problems they suffered towards the end of last year.
It has three key applications: diagnosis, prognosis and therapy. Research to date has concentrated on proteins relating to neurological diseases, cancer, rejection after organ transplantation, diabetes and obesity.
Proteins change in certain disease conditions; they become elevated or de-elevated. If they can be identified as Protein Markers they can enable doctors to diagnose diseases.
When drugs to patients are administered, protein change can be measured with blood tests to help with a prognosis to see how effective the prescribed therapy is.
Pearce believes proteomics will lead to proteins themselves being developed as therapies.
He said: 'With the current problems with drugs in development a different approach to clinical risk management is necessary for new regulatory requirements. We believe that proteomics technology will be one of the major contributors and beneficiaries of this'.
Citywire Verdict: A year ago the shares were 193.5p; last month they bottomed at 54.5p. The placing price of 59.5p may be significant. With today's 20% plus increase, those looking for quick profits may be too late. If you believe in the future of proteomics, and it is difficult not to, buy now and sit tight for two years.
http://www.citywire.co.uk/News/NewsArticle.aspx?VersionID=73219&MenuKey=News.Home&NewsPage=4